These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24699551)

  • 1. Cardioprotective effects of intracoronary adenosine in diabetic patients undergoing elective percutaneous coronary intervention.
    Shehata M
    Minerva Cardioangiol; 2014 Dec; 62(6):461-71. PubMed ID: 24699551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective effects of oral nicorandil use in diabetic patients undergoing elective percutaneous coronary intervention.
    Shehata M
    J Interv Cardiol; 2014 Oct; 27(5):472-81. PubMed ID: 25174952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina.
    Hwang J; Lee HC; Kim BW; Yang MJ; Park JS; Park JH; Lee HW; Oh J; Choi JH; Cha KS; Hong TJ; Song S; Kim SP
    J Cardiol; 2013 Aug; 62(2):77-81. PubMed ID: 23731922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The incidence of postoperative myocardial infarction and the left ventricular function in patients with type 2 diabetes mellitus after recanalization of chronic coronary occlusions].
    Petrenko IV; Petrenko OA; Popova MA; Mamedova SI; Urvantseva IA
    Ter Arkh; 2012; 84(10):28-32. PubMed ID: 23227496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary EnalaPrilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) study.
    Mangiacapra F; Peace AJ; Di Serafino L; Pyxaras SA; Bartunek J; Wyffels E; Heyndrickx GR; Wijns W; De Bruyne B; Barbato E
    J Am Coll Cardiol; 2013 Feb; 61(6):615-21. PubMed ID: 23290547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Singh M; Shah T; Khosla K; Singh P; Molnar J; Khosla S; Arora R
    Ther Adv Cardiovasc Dis; 2012 Jun; 6(3):101-14. PubMed ID: 22562999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention.
    Gordin J; Haider A; Swaminathan RV; Kim LK; Minutello RM; Bergman G; Wong SC; Feldman DN
    Am J Cardiol; 2012 Nov; 110(10):1397-404. PubMed ID: 22858186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracoronary ST-segment shift soon after elective percutaneous coronary intervention accurately predicts periprocedural myocardial injury.
    Balian V; Galli M; Marcassa C; Cecchin G; Child M; Barlocco F; Petrucci E; Filippini G; Michi R; Onofri M
    Circulation; 2006 Oct; 114(18):1948-54. PubMed ID: 17060382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The periprocedural myocardial damage prevention during elective percutaneous coronary intervention as a result of pharmacological preconditioning with an oral form of nicorandil in patients with stable coronary artery disease. Pilot study.
    Gostishchev RV; Soboleva GN; Samko AN; Rogoza AN; Minasyan AA
    Ter Arkh; 2018 Sep; 90(9):53-59. PubMed ID: 30701736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study.
    Lee CH; Low A; Tai BC; Co M; Chan MY; Lim J; Lim YT; Tan HC
    Eur Heart J; 2007 Jan; 28(1):19-25. PubMed ID: 17132650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
    Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): is related with lower levels of creatine kinase-MB (CK-MB) and troponin I?
    Foroughinia F; Salamzadeh J; Namazi MH
    Cardiovasc Ther; 2013 Oct; 31(5):268-73. PubMed ID: 23134549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.
    Kazmi DH; Kapoor A; Sinha A; Ambesh P; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel PK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S365-S371. PubMed ID: 30595291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention.
    Shehata M
    Am J Cardiol; 2014 Aug; 114(3):389-94. PubMed ID: 24927970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention.
    Li J; Xu JP; Zhao XZ; Sun XJ; Xu ZW; Song SJ
    Cardiology; 2014; 127(2):133-9. PubMed ID: 24335026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial).
    De Luca G; Iorio S; Venegoni L; Marino P
    Am J Cardiol; 2012 Jan; 109(2):202-7. PubMed ID: 22000773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial.
    Kim SJ; Kim W; Woo JS; Ha SJ; Kang WY; Hwang SH; Kang DG; Lee SU; Cho SK; Im JS; Kim W
    Int J Cardiol; 2012 Jun; 158(1):88-92. PubMed ID: 21256606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention.
    Pang Z; Zhao W; Yao Z
    Med Sci Monit; 2017 Jun; 23():2924-2930. PubMed ID: 28617765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of remote ischemic preconditioning on myocardial injury and endothelial function and prognosis after percutaneous coronary intervention in patients with acute coronary syndrome.
    Zhou FZ; Song W; Yin LH; Song ZF; Yang S; Yang FB; Liu JF; Song YG; Zhang HY; Zhang ZM
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4642-4648. PubMed ID: 29131250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention.
    Park H; Otani H; Noda T; Sato D; Okazaki T; Ueyama T; Iwasaka J; Yamamoto Y; Iwasaka T
    Int J Cardiol; 2013 Aug; 167(4):1547-51. PubMed ID: 22608892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.